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Abstract
Background: Human adipose-derived stromal cells (hASCs) represent a multipotent cell stromal cell type with proven
capacity to differentiate along an osteogenic lineage. This suggests that they may be used to heal defects of the craniofacial
or appendicular skeleton. We sought to substantiate the use of undifferentiated hASCs in the regeneration of a non-healing
mouse skeletal defect.
Methodology/Principal Findings: Human ASCs were harvested from female lipoaspirate. Critical-sized (4 mm) calvarial
defects were created in the parietal bone of adult male nude mice. Defects were either left empty, treated with an apatite
coated PLGA scaffold alone, or a scaffold with human ASCs. MicroCT scans were obtained at stratified time points post-
injury. Histology, in situ hybridization, and histomorphometry were performed. Near complete healing was observed among
hASC engrafted calvarial defects. This was in comparison to control groups that showed little healing (*P,0.01). Human
ASCs once engrafted differentiate down an osteogenic lineage, determined by qRT-PCR and histological co-expression
assays using GFP labeled cells. ASCs were shown to persist within a defect site for two weeks (shown by sex chromosome
analysis and quantified using Luciferase+ ASCs). Finally, rBMP-2 was observed to increase hASC osteogenesis in vitro and
osseous healing in vivo.
Conclusions/Significance: Human ASCs ossify critical sized mouse calvarial defects without the need for pre-differentiation.
Recombinant differentiation factors such as BMP-2 may be used to supplement hASC mediated repair. Interestingly, ASC
presence gradually dissipates from the calvarial defect site. This study supports the potential translation for ASC use in the
treatment of human skeletal defects.
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Introduction
Current surgical strategies for the healing of skeletal tissue
defects employ either autogenous grafts or alloplastic materials.
Although current approaches are in large part successful, they
come with inherent disadvantages. For example, alloplastic
materials have problems with rejection, infection and eventual
breakdown. Autologous tissues such as bone and bone marrow
grafts are often limited in availability, and require a substantive
operation with potential morbidity [1,2]. Thus, there remains a
pressing need for a suitable alternative to currently available
techniques for bone tissue repair. Our laboratory and others have
focused on harnessing the osteogenic capability of adipose-derived
stromal cells (ASCs) for the eventual repair of non-healing skeletal
defects [3–7].
Human adipose derived stromal cells (hASCs) are isolated from
the stromal vascular fraction of human lipoaspirate. They have
been described as a mesodermal stromal cell, with a proven ability
to differentiate along osteogenic, adipogenic, chondrogenic and
myogenic cell types, among others [8–19]. ASCs offer several
advantages over other multipotent cells (such as bone marrow
mesenchymal cells) for tissue engineering purposes [6,18,20].
ASCs are easily obtainable by a commonly used surgical
procedure. ASCs are highly proliferative and thus are available
in abundance. Moreover, hASCs show robust mineralization
within one week of in vitro differentiation [21]. Previous studies
have attempted to utilize hASCs for the regeneration of skeletal
defects, but have met with limited success [22,23]. Our study
sought to assess the capacity of freshly derived and undifferentiated
human ASCs to regenerate a non-healing mouse defect.
Our laboratory and others have previously employed a calvarial
defect model for both the evaluation of normal healing, and the
use of ASCs for the healing of critical sized (or non-healing) defects
[24–30]. Previously, we have demonstrated that ASCs of mouse
origin successfully heal a critical sized mouse defect [30]. In an
effort to realize the bench to bedside application of ASCs in
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human origin to heal calvarial defects. Human and mouse ASCs
differ in multiple fundamental aspects [31,32], and so this leap from
mouse to man is by no means insignificant. To avoid incompat-
ibility of xenografted tissue, an athymic mouse model was utilized
(Charles Rivers, Crl:CD-1 Foxn1
nu) [33]. Herein, we observed that
freshly isolated human ASCs successfully heal a critical sized mouse
calvarialdefect. Subsequently we demonstratethatwe canaugment
this osteogenic healing by supplementing BMP-2.
Results
Human ASCs undergo in vitro osteogenic differentiation
and can be successfully grafted unto a calvarial defect
First, the osteogenic differentiation of human (h)ASCs was
verified using standard osteogenic differentiation medium (ODM)
in vitro over a period of seven days (Figure 1A,B). Alkaline
phosphatase enzymatic activity was assessed at 3 days differenti-
ation, which appears purple and is representative of early
osteogenic differentiation (Figure 1A). Bone nodule formation
was visualized after 7 days differentiation, as assessed by Alizarin
red S staining (Figure 1B). In both cases, hASCs showed robust
staining indicative of in vitro osteogenic differentiation.
Next, successful hASC in vivo cell engraftment was confirmed.
PLGA scaffolds were seeded as described in the methods section.
Representative animals from each group were sacrificed at 1 week.
Cells were stained with DAPI nuclear counterstain, appearing
blue. Fluorescent in situ hybridization (FISH) was performed
specific for human sex chromosomes. This was performed to
confirm viability of hASCs directly engrafted, as well as their cell
progeny. Results showed, as expected, that those cells within the
defect site were positive for human-X chromosome (Figure 1C).
In contrast, those cells not within the defect site were negative,
confirming the success of our xenograft and the specifity of our
FISH analysis (Figure 1D). Thus, not only were hASCs
successfully engrafted, they remained viable and contained within
the defect site. Having demonstrated successful hASC engraft-
ment, we next inquired as to whether hASCs would successfully
heal this surgically created defect.
Human ASCs heal critical size mouse calvarial defects by
gross examination
First, three experimental groups were assayed over 8 weeks
healing post injury: 1) empty defects, 2) scaffold only, and 3)
undifferentiated hASCs in combination with a scaffold (n=5 per
group). After 8 weeks, all mice were sacrificed for gross and
histological analysis. Bird’s eye photographs after 8 weeks verified
a near complete lack of healing in empty defects (Figure 2). Thus
the brain, meninges and meningeal vessels were grossly apparent
(left, Figure 2). In marked contrast, those defects engrafted with
hASCs showed robust bony regenerate throughout (right,
Figure 2).
Human ASCs heal critical size mouse calvarial defects by
microCT
To assess bone regeneration, microCT scans were next
performed at time 0 as well as 1, 2, 4, 6 and 8 wks post injury.
Figure 1. Human ASC Differentiation and Engraftment. (A,B) Human ASCs undergo in vitro osteogenic differentiation. (A) Gross photograph of
alkaline phosphatase staining at 3 days differentiation. (B) Gross photograph of alizarin red staining at 7 days differentiation. (C,D) Fluorescent in situ
hybridization for human X chromosome, appearing green. Nuclear counterstain appearing blue. (C) As expected, the majority of cells within the
defect site at one week were of human origin, showing two X chromosomes. (D) Specificity of FISH analysis was ensured, as sites other than the
defect were negative.
doi:10.1371/journal.pone.0011177.g001
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empty showed little or no healing by microCT at up to 8 wks (top
row, Figure 3A). In comparison, defects treated with scaffold only
showed small peninsulas or islands of bony regenerate as well as
some healing from defect edges inward, but the majority of the
defect showed no osseous healing (middle row, Figure 3A).
Finally, defects treated with hASCs grafted onto a scaffold showed
robust healing (bottom row, Figure 3A). By only 4 weeks post-
injury, near complete healing was appreciated by microCT. Thus,
by both gross examination and microCT imaging, it appeared that
hASCs when grafted onto a PLGA scaffold successfully heal a
critical size mouse calvarial defect.
Quantification of microCT images was next performed.
Percentage healing of the defects was evaluated by quantifying
pixels in the defect using Adobe PhotoShop. Percentage healing
was determined by dividing the defect area by the defect size
immediately postoperatively (Figure 3B). Results showed that
empty defects healed by less than 10% over the course of 8 wks
(grey bars, Figure 3B). Defects treated with scaffold only showed
a significant increase in healing percent, amounting to 42% after
8 wks (blue bars, Figure 3B). Finally, defects treated with hASCs
showed an approximate 75% healing after 6 wks and completely
healed by 8 weeks (yellow bars, Figure 3B).
Human ASCs heal critical size mouse calvarial defects by
histological analysis
We next sought to verify our gross and microCT findings by
direct histological examination. Serial sections were generated
through each defect; approximately 100 slides were made through
each defect. Every tenth slide was stained to examine the entirety
of the defect (Figure 4A). Results showed that empty defects had
little or no bony regenerate by 8 wks by both aniline blue and
pentachrome staining (top left, Figure 4A). The mid defect
showed only dural tissue, without evidence of bone (middle left,
Figure 4A). Finally, the defect edge showed an abrupt cutoff from
old bone to absence of bone (bottom left, Figure 4A). In effect, no
ossification was observed among empty defects. Among scaffold
only defects, some ossification was apparent by aniline blue and
pentachrome (middle columns, Figure 4A). This was most
apparent at the defect edge, where a thin layer of osteoid was
apparent on the ectocranial surface (middle columns, Figure 4A).
Finally, and in marked contrast to the other groups, robust
trabeculated bone formation was apparent in hASC treated
defects (right columns, Figure 4A). For example, large amounts of
yellow stained woven bone were appreciated throughout the defect
site (right columns, Figure 4A).
Next, by histomorphometric measurements we sought to
substantiate our findings (Figure 4B,C). New bone regenerate
within the defect site was measured using Adobe Photoshop as
previously described [34]. As well, defect width was measured on
the same slides. Results showed a significant increase in new bone
area among hASC treated defects (Figure 4B). This was
accompanied by a substantial decrease in the defect width
(Figure 4C). Thus, by gross analysis, microCT imaging and
histological examination, human ASCs were observed to heal a
critical size mouse calvarial defect.
ASCs directly undergo osteogenic differentiation in vivo
ASC engraftment led to defect ossification by all markers
examined, but do hASCs directly undergo in vivo osteogenic
differentiation? To answer this hASCs transduced with a human
lentivirus encoding green fluorescent protein (GFP), permitting in
situ detection of human cells were utilized. Next, GFP immuno-
histochemistry was performed on GFP+ hASC engrafted defects at
2 week postoperatively. At 2 wks, GFP+ cells were detected in the
defect site (Figure 5A, upper left). As a negative control, the
contralateral (or uninjured) side of the calvaria was imaged, which
verified the specificity of GFP immunostaining (Figure 5A,
upper right). Next, staining for osteogenic markers (COL1A1 and
RUNX2) was performed on adjacent slides to those used for GFP
analysis, using in situ hybridization (Figure 5A, middle and
bottom rows). Results showed that those cells which were GFP+
(indicating human origin) also stained for osteogenic markers. We
also show the contralateral uninjured side of the defect to
demonstrate the specificity of the stain which can be seen in the
periostium (Fig. 5A, right column).
As further verification, qRT-PCR analysis was performed on
calvarial defects for the presence of human osteogenic genes
(Figure 5B). Expression of human (h)GAPDH, hALP and hRUNX2
expression were found at both 1 and 2 wks. As a negative control,
Figure 2. Gross appearance of calvarial defects. (A,B) Four millimeter calvarial defects were created in the right parietal bone of male p60 nude
mice. After 8 wks healing, mice were sacrificed, a longitudinal incision was made over the cranium, and the skull was exposed for photographic
documentation. On the left, a representive empty defect, in which very little osseous healing as occurred. Thus, the brain, meninges and meningeal
vessels are visualized. On the right, a representative defect grafted with hASCs on a PLGA scaffold. Neither brain nor meninges are visible. Instead a
new layer of woven bone has healed the critical size defect. Dashed lines encircle the original defect. N=5 per group in total. Box in bottom left is a
magnified view.
doi:10.1371/journal.pone.0011177.g002
ASCs Heal Calvarial Defects
PLoS ONE | www.plosone.org 3 June 2010 | Volume 5 | Issue 6 | e11177defects without hASC engraftment showed no amplification,
confirming specificity for human genes (data not shown).
Moreover, both hALP and hRUNX2 showed increased expression
from 1 to 2 wks when normalized to hGAPDH. Thus and in
summary, these data suggested that hASCs express osteogenic
genes in vivo during a time period corresponding to cranial defect
ossification, a finding supporting osteogenic differentiation of
engrafted hASCs.
ASCs do not persist in the healed mouse calvarial defect
beyond two weeks
Our prior FISH analysis proved successful initial hASC
engraftment and osteogenic differentiation, but what happens to
engrafted hASCs overtime? For this purpose, we again employed
FISH analysis for human sex chromosome at 1, 2, 4 and 8 weeks
postoperatively (Figure 6A). At 1 week post-injury, the majority of
cells within the defect site stained positively for human X
chromosome, indicating their hASC origin (Figure 6A, left
column). At 2 weeks, numerous individual cells still stained
positively, however they were interspersed with areas in which cells
were distinctly of mouse origin (Figure 6A, left column). At 4
weeks and 8 weeks, a virtual absence of FISH positive cells was
identified (Figure 6A, left column). This somewhat surprising
result was verified by qRT-PCR at 8 weeks. 1 ug of RNA from the
defect site was reverse transcribed. Using standard parameters
commonly employed in our laboratory, human genes did not
reach Ct values after 40 cycles. During the same assay, mouse
Gapdh showed robust amplification (data not shown). Taken
together, these data suggest that although hASC engrafted defects
successfully heal, human cells do not persist in the defect site. Two
Figure 3. Calvarial healing by microcomputed tomography. Four millimeter calvarial defects were created in the parietal bone of p60 nude
mice. Treatment groups included empty defects, defects treated with scaffold only, or bone defects treated with hASCs within a scaffold. (A) MicroCT
scanning up to 8 weeks revealed near complete lack of healing among empty defects. Small peninsulas or islands of bone nodule formation were
observed among scaffold only defects. In marked contrast, hASCs impregnated scaffolds were observed to nearly heal within 4 weeks. (B)
Quantification of MicroCT. At up to 8 wks, healing of defects represented as a fraction of total defect area was quantified by microCT images. N=5
per group, *P,0.01.
doi:10.1371/journal.pone.0011177.g003
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not persist due to cell death. TUNEL assays were performed at 1,
2, 4 and 8 weeks. Sparse TUNEL + cells were noted within the
defect site at all time points (Fig. 6A, middle column), thus cell
death could not explain the apparent lack of human cell
persistence within the defect site. Second, active bone turnover
could explain this phenomenon, such that hASC produced bone
may have been gradually replaced overtime with mouse host
derived tissue. Interestingly, this did appear to be the case, as an
increasing intensity of TRAP staining was noted in the defect site
from 2–8 weeks postoperatively (Fig. 6A, right column). Taken
together, these data suggest that hASC-engrafted PLGA scaffolds
heal a critical size mouse calvarial defect, however, by 8 weeks the
healed defect is predominantly of host mouse origin.
In our previous study utilizing mouse ASCs in a calvarial defect,
we observed the persistence of mouse donors cells at 2 weeks
postoperatively [30]. In more detail, we sought to ascertain
whether mouse ASCs in similarity to hASCs did not persist
overtime. For this purpose, mASCs were harvested from
transgenic mice expressing Firefly Luciferase (Fig. 6B). Luc+
mASCs were engrafted in wild-type CD-1 mice and Luciferase
activity was imaged weekly thereafter (Fig. 6B). At 0 through 2
weeks, luciferase activity was observed in the defect site, however
the quantity of luciferase activity was noted to significantly
attenuate thereafter (right, Fig. 6B for quantification). Thus in
summary, among ASCs of both mouse and human origin, a
significant dissipation in cell number was observed in the initial
two weeks following implantation.
BMP-2 enhances human ASC mediated bony healing in
vivo
Various differentiation factors have been shown to enhance in
vitro hASC osteogenic differentiation, including bone morphoge-
netic protein (BMP)-2 [29,32]. We first sought to verify the pro-
osteogenic effect of rhBMP-2 on hASC in vitro differentiation [35].
Osteogenic differentiation was performed over 1 week in culture
with or without rhBMP-2 (100 ng/ml, a concentration derived
from dose curves performed). By all markers examined, osteogenic
differentiation was significantly enhanced by rhBMP-2 addition to
ODM, (Fig. 7A,B). This included alkaline phosphatase staining
and quantification, Alizarin red staining of bone nodules, and
specific gene expression by qRT-PCR (ALP, COL1A1). We next
Figure 4. Calvarial healing by histology. (A) Histology at 8 weeks post injury. Serial sections throughout the defect site were created at 8 weeks
post injury. Representative slides were stained with aniline blue, in which osteoid appears dark blue. As well, select slides were stained with
Pentachrome, in which bone appears bright yellow. At low magnification (2.5x) the empty defects showed complete lack of new bone formation (left
columns). Some small amount of woven bone was appreciated among defects treated with an empty scaffold (middle columns). However, near
complete ossification was observed in defects treated with hASCs in a scaffold (right columns). This was accompanied by an increased thickness in
the bony regenerate. (B) Quantification of bone formation at 8 weeks post injury by histological analysis. Average bone formation from every tenth
slide was obtained using Adobe Photoshop analysis of aniline blue staining. Results showed a significant increase in bone formation with hASCs in
comparison to other groups. (C) Average defect width was calculated on the same specimens. As expected a significant decrease in defect width was
appreciated with hASC implantation, with many slides showing complete healing. N=5 per group, *P,0.01.
doi:10.1371/journal.pone.0011177.g004
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suspension was delivered to the defect site via simple subcutaneous
injection on postoperative days 1–3 and followed by microCT
(Figure 7 C,D). Results showed that significant healing was
observed among control hASC engrafted defects, over 55% after 8
weeks healing (Fig. 7C, top). In comparison, significantly more
robust healing was observed with addition of rhBMP-2 to hASC
treated defects (Fig. 7C, bottom). This was subsequently
quantified, yielding a significant increase in bone formation
among rhBMP-2/hASC treated defects (Fig. 7D).
Discussion
This study extends what is already known regarding the
potential use of ASCs for osseous tissue repair and regeneration.
Prior studies have focused on ASCs from multiple species,
including mouse, rabbit and human [9,18,22]. ASCs have a
capacity to undergo rapid osteogeneic differentiation, and in our
observations show robust mineralization within one week in vitro
[36]. Our laboratory and others have documented the ability of
ASCs derived from rodent species to heal surgically created cranial
defects [22,23,30]. Our study sought to address two specific
questions. First, can ASCs of human origin regenerate a non-
healing calvarial defect? Secondly, can this be performed without
the need for pre-differentiation? We believe this second question to
be clinically relevant, as the less time hASCs need to expand in
vitro, the less likelihood of in vitro contamination, the timelier the
transfer to in vivo host, and perhaps most importantly the shorter
the in-hospital patient stay.
We observed that freshly isolated, undifferentiated hASCs
successfully healed a critical sized cranial defect. Interestingly,
we observed a much more rapid healing of defects engrafted with
human ASCs than that of previous studies in ASCs of other species
[30]. The fact that substantive differences exist between mouse
and human ASCs upon in vivo engraftment is in part to be
expected, as vast in vitro differences do exist. For example, human
ASCs undergo much more rapid in vitro osteogenesis [32].
Moreover, hASC osteogenesis goes unperturbed even in the
presence of growth factors such as FGF-2 or TGF-b1 [31]. These
differences are exciting for multiple reasons. First, if we are able to
fully document those factors that play a role in the enhanced
osteogenesis observed in human as compared to mouse cells, we
may further capitalize on them via gene or protein manipulation.
Secondly, the robust osteogenic response of human ASCs suggests
that in the future even a relatively large sized defect may be
successfully repaired via hASC autologous transfer.
In fact, small studies have already examined the potential use of
hASCs to heal skeletal defects in the human patient. Defects of the
cranium [37], maxilla and mandible [38] have been either healed
or enabled to heal faster with the use of hASCs [39]. Methods of
hASC usage have varied dramatically and have included
combination with bone chips, the use of various osteoconductive
scaffolds as well as recombinant proteins. For example, Mesimaki
et al. used a novel microvascular flap with hASCs, beta-tricalcium
phosphate and BMP-2 to heal a large defect in the maxilla,
reporting good outcomes up to 8 months post-operatively [40].
Larger scale studies must verify these findings, however we believe
that the optimum delivery method and cytokine stimuli can be fine
tuned utilizing our nude mouse model.
Our study also found that hASCs require no special additions to
medium prior to engraftment. Various cytokines and other factors
are known to stimulate osteogenic differentiation among ASCs.
These include bone morphogenetic proteins (BMPs) [32], Insulin
like growth factor-1 (IGF-1) [21], histone deacetylase inhibitors
(HDIs) such as valproic acid [34], and Sonic Hedgehog [36]. We
found that the use of such factors (in this study BMP-2) in addition
to hASC engraftment more rapidly healed a defect. BMPs have
been thoroughly studied in the differentiation of ASCs by
Figure 5. Human ASCs undergo osteogenic differentiation in vivo. Human ASCs transduced with a GFP encoding lentivirus were seeded in
calvarial defects. (A) Histological analysis at 2 wks postoperative. The defect site (left) and contralateral aspect of the skull (right) from identical
sections are imaged to show specificity of staining. (A, top) GFP immunohistochemistry, depicting evidence of human cells which appear brown. The
contralateral side shows no GFP signal demonstrating the specificity of the stain. (A, middle) Type I Collagen (COL1A1) expression by in situ
hybridization. (A, bottom) Runt related transcription factor 2 (RUNX2) expression by in situ hybridization. Staining can be seen in the uninjured
contralateral periostium demonstrating specificity and can also be seen within the defect site. (B) Human osteogenic gene expression by qRT-PCR at
1 and 2 wks post-injury among hASC engrafted defects, including hALP, hRUNX2,* P,0.01.
doi:10.1371/journal.pone.0011177.g005
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of neutralizing antibodies, viral over expression and siRNA
[22,32,41,42]. These studies suggest that BMP signaling is
sufficient to enhance ASC osteogenic differentiation and con-
versely BMP/BMPR1B signaling necessary for the normal
osteodifferentiation to occur. Various methods may exist for the
potential delivery of such growth factors. Simple subcutaneous
injection was sufficient in the present study. However, a more
sophisticated approach may utilize hASCs engrafted onto a defect
laden or impregnated with growth factors to promote even more
robust bone formation. Alternatively, a short in vitro pretreatment
of hASCs followed by in vivo engraftment without recombinant
protein may be just as advantageous without potentially
stimulating neoosteoclastogenesis [27,29]. The benefit of the
technique presented in this manuscript, however, is that it does
not require any pre-treatment of the hASCs. This ability to use the
harvested hASCs immediately will allow the surgeon to perform a
reconstruction in one step and also may be advantageous from a
Food and Drug Administration (FDA) standpoint. Thus we
anticipate the use of our nude mouse model for the future fine-
tuning of hASC mediated calvarial regeneration.
One potentially puzzling aspect of our study was the fact that
hASCs were not found to predominantly persist within our cranial
defect model after 2 weeks engraftment. Prior studies have
Figure 6. Bone turnover within a calvarial defect. (A, far left column) FISH staining for human sex chromosomes in hASC engrafted defects
from 1–8 weeks postoperatively. Human X chromosome appears green, while DAPI nuclear counterstain appears blue. 1006magnification. (A, mid
left column) TUNEL staining in hASC engrafted defects from 1–8 weeks postoperatively. TUNEL positive cells appear green, while DAPI nuclear
counterstain appears blue. (A, far right column) TRAP staining in hASC engrafted defects from 1–8 weeks postoperatively. TRAP positive cells appear
red/purple. (B) Luciferase activity in defects engrafted with Luc+ mouse ASCs. Images from a representative mouse (left), and quantification (right).
Red represents the highest level of activity, followed by yellow, blue, dark blue, and purple. N=3 animals. *P,0.01.
doi:10.1371/journal.pone.0011177.g006
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immunocompromised mouse similar to our study. For example,
after intravenous injection, hASCs were found to persist within the
mouse even after 8 months [43]. In contrast, the simple
subcutaneous injection of hASCs was found to dissipate after as
little as 5 days in other models [44]. In current studies in our
laboratory, fat grafting into a subcutaneous pocket has been
performed using human tissue in the same athymic CD-1 mouse.
We have thus far shown continued presence of human cells up to 3
months postoperatively (data not shown). A bone defect is a much
different in vivo environment, however, which has both inflamma-
tion and bone turnover. How would these factors influence
engrafted hASC persistence? Our results suggested that the
persistence of hASCs within a calvarial defect site is limited to
approximately two weeks. This was not explained by impaired cell
survival, but rather by clear bone turnover within the defect site.
Interestingly, these findings were recapitulated by the use of mouse
ASCs expressing Firefly Luciferase, suggesting that this finding is
not species specific. We would argue that these findings enhance
rather than diminish the significance of our results. An ideal
substance for reconstruction, whether prosthetic or autologous,
would be one that stimulates the host’s reparative processes so that
the final healed tissue is of host origin. Thus, the armamentarium
of a future reconstructive surgeon could consist for example of
biomimetic, biodegradable scaffolds through which host tissue
could easily migrate. It appears from our study that ASCs
complement this paradigm nicely, as their engraftment led to
complete healing a calvarial defect, but without long-term
persistence of the foreign xenografted material. Thus, while
dissipation of fat grafts are of disadvantage in soft tissue
Figure 7. BMP-2 increases hASC osteogenesis in vitro and in vivo. (A,B) Recombinant human (rh)BMP-2 was first added to standard osteogenic
differentiation medium (ODM) to verify its effects on in vitro hASC osteogenic differentiation. (A, top) Alkaline phosphatase (ALP) staining, appearing
purple, at 3 days differentiation with or without rhBMP-2 (100 ng/ml). (A, bottom) Alizarin red staining, appearing red, at 7 days differentation witho r
without rhBMP-2 (100 ng/ml). (B) From top to bottom: relative ALP gene expression by qRT-PCR at 3 days, relative ALP enzymatic activity normalized
to protein content at 3 days, and relative COL1A1 gene expression by qRT-PCR at 7 days. (C,D) Next, rhBMP-2 was delivered to hASC-engrafted
defects by subcutaneous injection on days 1–3 postoperatively. Healing was assessed by serial microCT examination and quantification (C) MicroCT
healing from 1–8 weeks with hASCs alone or hASCs + rhBMP-2. (D) Quantification of fraction healing from 1–8 weeks postoperatively. N=3, *p,0.05.
doi:10.1371/journal.pone.0011177.g007
ASCs Heal Calvarial Defects
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real benefit in the case of cell-based strategies for skeletal
reconstruction.
In conclusion, undifferentiated human ASCs successfully heal
critical sized mouse calvarial defects. Thus, human ASCs
represent a promising cell type for future translational efforts in
the autogenous repair of skeletal defects. BMP signaling may
beneficially modulate hASC mediated bony repair. We believe
that the hASC/nude mouse model has utility in the in vivo
optimization of hASC mediated skeletal tissue regeneration.
Methods
Ethics Statement and Human ASC Harvest
ASCs were harvested from human lipoaspirate as previously
described [21]. All research involving hASCs has been approved
by the Stanford institutional review board, protocol #2188 and
#9999. Written informed consent was obtained for all patients,
information regarding patient age and sex was recorded, in all
other respects anonymity was maintained (Figure S2, S3).
Briefly, specimens were washed in dilute Betadine, then phosphate
buffered saline (PBS), and digested with a 0.075% Type II
collagenase in Hank’s Balanced Salt Solution at 37 degrees Celsius
under agitation for 30 min. Next, collagenase was inactivated by
10% Fetal Bovine Serum (FBS) in PBS. The stromal vascular
fraction (SVF) was then pelleted, the supernatant discarded, and
the cell pellet resuspended and filtered through a 100 micrometer
strainer. Primary cultures were established at 37 degrees Celsius,
21% O2,5 %C O 2. For all assays, specimens were obtained from
female patients under fifty years of age, from the flank and thigh
subcutaneous regions only. In total, hASCs were pooled from five
patients for all assays. Mean patient age was 46.5 years, mean BMI
was 26.1 kg/m
2, with all patients weighing less than 30 kg/m
2.I n
addition, for select experiments mouse ASCs were derived from
the inguinal fat pads [34] of transgenic CD-1 mice with
constitutively active Firefly luciferase in order to quantify cell
persistence upon in vivo engraftment. Cells were expanded for
72 hours in growth medium (DMEM, 10% FBS, 1% penicillin/
streptomycin), passaged by trypsinization and placed on scaffolds
or seeded for subsequent in vitro experiments.
In vitro differentiation assays
To verify that hASCs were capable of osteogenic
differentiation and determine their responsiveness to
recombinant human (rh)BMP-2, in vitro assays were
performed. Human ASCs were plated in 6 well plates at a
concentration of 100,000 cells/well. Cells were treated with
standard osteogenic differentiation medium (ODM) with or
without recombinant human (rh)BMP-2 (100 ng/mL). Dose
curves were performed to arrive at this optimum concentration
(10–400 ng/mL). Alkaline phosphatase staining and quantification
of enzymatic activity was performed at 3 days differentiation as
previously described [21]. Alizarin red staining was performed at 7
days differentiation as previously described [45]. Specific gene
expression was analyzed at 3 days differentiation by quantitative
RT-PCR, standardized to housekeeping gene expression [46].
Quantitative real-time polymerase chain reaction was carried out
using the Applied Biosystems Prism 7900HT Sequence Detection
System. Specific primers are listed in Figure S1.
GFP Transfection
First passage hASCs were allowed to reach 80% confluency in a
10 cm plate. Subsequently, cells were treated with a turboGFP
lentiviral construct (Open Biosystems) in regular growth media in
the presence of 8 ug/ml plybrene. After 12 hours, the cells were
observed to have green fluorescence verifying transfection. Cells
were subsequently treated with puromycin to select only those cells
successfully transfected.
Calvarial Defects
Animals were obtained from Charles Rivers laboratories and
housed in the Research Animal Facility on Stanford University
campus. The facility, accessed by authorized personnel only, is
temperature, ventilation and illumination controlled. Mice have
access to feed and water ad libitum. All mice housing conforms to
NIH Guide standards, the Animal Welfare Act, and ILAR guide.
Transportation of animals was performed based on the ‘‘Guide-
lines for Transportation of Animals from the Stanford Centralized
Animal Facilities,’’ developed by the Administrative Panel on
Laboratory Animal Care (A-PLAC). All animal procedures were
approved by Stanford A-PLAC, Protocol #9999. Non-healing,
critical-sized (4 mm) calvarial defects were created in the right
parietal bone of adult (60 day-old) male CD-1 nude mice (Charles
Rivers, Crl:CD-1 Foxn1
nu) using a high-speed dental drill. For
mouse ASC experiments, CD-1 wildtype mice were used. Animals
were anesthetized using 20 mg/kg Ketaset, 1.5 mg/kg xylazine,
and 0.2 mg/kg acepromazine maleate. After cleaning the surgical
site with Betadine, an incision was made just off the sagittal
midline to expose the right parietal bone. The pericranium was
removed using a sterile cotton swab. Using diamond-coated
trephine bits and saline irrigation, unilateral full-thickness critical-
size calvarial defects were created in the non-suture associated
right parietal bone. Importantly, the dura mater was left
undisturbed.
In preparation for implantation, scaffolds were seeded with
female hASCs. 150,000 cells were resuspended in 25 ml of growth
media (DMEM, 10% FBS, 1% penicillin/streptomycin), and
placed directly onto the scaffold for 30 minutes (25 ml of media
without cells were used for empty scaffold controls). The scaffolds
were subsequently submerged in 100 ml of growth media for
24 hours incubation. Before implantation, cell-seeded scaffolds
were copiously rinsed in sterile PBS to prevent transfer of medium-
derived growth factors or immunogens. Animals were split equally
into three treatment groups: 1) empty defects in which a 4 mm
defect was created but left empty, 2) scaffold only, in which a
PLGA scaffold without cells was placed in the defect site and, 3)
hASCs and scaffold, in which hASCs were impregnated in a
scaffold (n=5 per group). Finally, the skin was sutured with 6-0
vicryl and the animal was monitored per established post-operative
animal care protocols. Animals were allowed to recover under
heat lamps for a period of up to 6 hours before being returned to
the animal facility. Thereafter, animals were observed once daily
for three days and weekly thereafter to ensure postoperative
recovery.
In order to more robustly heal defects, recombinant human
(rh)BMP-2 was delivered via subcutaneous injections. Subcutane-
ous injections of a 50 ul cytokine suspension in normal saline were
performed on days 1, 2 and 3 postoperatively (500 ng BMP-2 daily
in 50 ul) (R&D systems). Animals were sedated with Aerrane and a
wheal was made just overlying the defect site. Animals were
allowed to recover before being returned to the animal facility.
Four groups were performed: 1) scaffold only with vehicle injection
as a control, 2) scaffold only with rhBMP-2 injection, 3) hASC
engrafted scaffold with vehicle injection as a control, and 4) hASC
engrafted scaffold with rhBMP-2 injection (N=3 per group).
Finally, for select experiments we utilized transgenic Luciferase+
CD-1 mice. Luc+ mASCs, derived from inguinal fat pads were
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CD-1 adult (60 day old) mice (N=3).
Scaffold creation
Apatite-coated PLGA scaffolds were fabricated from 85/15
poly(lactic-co-glycolic acid) (inherent viscosity =0.61 dL/g, Bir-
mingham Polymers) by solvent casting and a particulate leaching
process. Briefly, PLGA/chloroform solutions were mixed with
2002300 m diameter sucrose to obtain 92% porosity (volume
fraction), and compressed into thin sheets in a Teflon mold. After
freeze-drying overnight, scaffolds were immersed in three changes
of double-distilled (dd) H2O to dissolve the sucrose, and gently
removed from the Teflon plate with a fine-tip spatula. After
particulate leaching, all scaffolds were disinfected by immersion in
50%, 60% and 70% ethanol for 30 min each, followed by three
rinses of ddH2O. All scaffolds are then dried under a laminar flow
hood.
In Vivo Imaging
Micro computed tomography was performed, using a high-
resolution MicroCAT II
TM (ImTek Inc., Knoxville, TN) small
animal imaging system. Live animals were imaged after sedation
with Aerrane (Isoflurane, Baxter Healthcare Corporation, Deer-
field IL). The following settings were used: x-ray voltage of
80 kVp, anode current of 500 mA and an exposure time of 500
milliseconds for each of the 360 rotational steps. The 2D
projection images were used to reconstruct tomograms with a
Feldkamp algorithm, using a commercial software package (Cobra
EXXIM, EXXIM Computing Corp., Livermore, CA), resulting
into a resolution of 80 mm. The duration of one scan was 9.5
minutes. 3D reconstructions were generated by MicroView
software (GE Healthcare, London, Canada). Every mouse was
scanned with a CT-phantom and isosurface was set in Hounsfield
units according to the phantom which included hydroxyapetite,
water and air.
In order to track Firefly Luciferase activity after engraftment
of Luc+ mASCs, the In Vivo Imaging System (IVIS) was used.
Mice were anesthetized and luciferin (150 mg/kg in 200 mL)
injected into the peritoneal cavity. After 10 minutes, animals
were then placed in the IVIS 200B
TM imaging system and
imaged for 3 minutes at large binning. Luciferase activity at the
calvarial injury site was quantified weekly postoperatively using
Living Image 3.2.
Histologic Analyses
At 1, 2, 4 and 8 weeks, animals were sacrificed by CO2
asphyxiation and cervical dislocation to confirm radiographic
findings. Calvaria were harvested, formalin-fixed, decalcified in
19% EDTA and paraffin-imbedded. Aniline blue staining was
performed on every 10
th section throughout the sample to provide
detailed histology of the regenerate. Histomorphometry was
performed on every 10
th slide throughout the defect using Adobe
Photoshop as previously described [34]. Next, select slides were
stained with Pentachrome, in which bone appears bright yellow.
Alkaline phosphatase staining was performed on select slides, as
previously described [34,47]. To examine cell death and bone
turnover, TUNEL and TRAP staining was performed as
previously described [47]. GFP immunohistochemistry was
performed on select slides as previously described [36], per
manufacturers instructions. Finally, Runx2 and Col1a1 in situ
hybridization was performed on select slides, as previously
described [47].
Fish Analysis for sex chromosomes
Tissue sections were pretreated by standard protocol using the
VP2000
TM slide pretreatment instrument (Abbott Molecular).
Briefly, slides were deparaffinized, digested with a 10% pepsin
solution at 37uC (Protease I, VP2000
TM Protease Buffer; Abbott
Molecular), pre-treated with a sodium thiocyanate solution at
80uC (VP2000
TM Pretreatment Solution; Abbott Molecular), re-
fixed in 10% buffered formalin, and dehydrated in an ethanol
series. Slides were denatured with a VysisHHYBrite instrument at
73uC for six minutes and hybridized for 48 hours at 37uC with a
dual-color DXZ1/DYZ3 probe set, specific for the centromeres of
the human X and Y sex chromosomes, respectively (Abbot
Molecular). Slides were washed with 2xSSC/0.3% NP-40 at 73uC
for two minutes, counterstained with DAPI and analyzed with an
Olympus BX51 microscope, appropriate fluorescent filters and a
CytoVisionH imaging system (Genetix, San Jose).
Polymerase chain reaction
RNA was isolated from formalin fixed paraffin embedded slides
using the RecoverAll RNA kit (Ambion, Cat #AM1975). The
defect site of 6 slides (approximately 24 sections) was used as tissue
starting material. After quantification by spectrophotometry,
reverse transcription was performed with Taqman Reverse
Transcription Reagents (Applied Biosystems, Foster City, CA).
Quantitative real-time polymerase chain reaction was carried out
using the Applied Biosystems Prism 7900HT Sequence Detection
System in triplicate wells [48]. Specific primers are listed in
Figure S1.
Statistical analysis
Means and standard deviations were calculated from numerical
data, as presented in the text, figures and figure legends. In figures,
bar graphs represent means, whereas error bars represent one
standard deviation. Statistical analysis was performed using the
ANOVA two-factor with replication when more than two groups
were compared. In addition, the Welch’s two-tailed t-test was used
when standard deviations between groups were unequal. Inequal-
ity of standard deviations was verified by employing the Levene’s
test. *P#0.01 was considered to be significant.
Supporting Information
Figure S1 Sequences used in real-time polymerase chain
reaction.
Found at: doi:10.1371/journal.pone.0011177.s001 (0.03 MB
DOC)
Figure S2 Informed Consent Sample. This document is a
sample of our Informed Consent, which is signed by each human
patient from which liposuction aspirate is harvested for cell
derivation.
Found at: doi:10.1371/journal.pone.0011177.s002 (0.06 MB
DOC)
Figure S3 IRB Approval Letter. This IRB Approval Letter from
the Stanford Institutional Review Board supports the harvest and
study of human adipose derived stromal cells.
Found at: doi:10.1371/journal.pone.0011177.s003 (0.09 MB
PDF)
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